de Santana Silva Íris Terezinha Santos, Fehlberg Hllytchaikra Ferraz, Ferreira Fabrício Barbosa, da Silva Murillo Ferreira, Dos Santos Pérola Rodrigues, Porto Vinicius Moreira, Dias João Carlos Teixeira, Albuquerque George Rego, Mariano Ana Paula Melo, Gadelha Sandra Rocha, Kaneto Carla Martins
Programa de Pós-graduação em Biologia e Biotecnologia de Microrganismos, Universidade Estadual de Santa Cruz, Ilhéus, Bahia, Brazil.
Laboratório de Farmacogenômica e Epidemiologia Molecular (LAFEM), Universidade Estadual de Santa Cruz, Ilhéus, Bahia, Brazil.
Sci Rep. 2025 Jul 22;15(1):26636. doi: 10.1038/s41598-025-04062-9.
SARS-CoV-2, the virus responsible for COVID-19, exhibits structural differences compared to other coronaviruses that impact transmission dynamics and host response. Although vaccines have reduced severe hospitalizations and deaths, understanding the infection remains challenging, and finding viable biomarkers for disease severity would be beneficial. In this context, microRNAs (miRNAs) are a set of small non-coding RNAs that have emerged as potential biomarkers for numerous diseases. However, assessing miRNA expression requires the normalization of RT-qPCR data using appropriate endogenous reference genes. The selection of these reference genes remains a major challenge, directly impacting the accuracy of expression analyses. Although several small RNAs, including snRNAs, have been evaluated, there is still no consensus regarding the optimal reference genes for the normalization of plasma miRNA expression data in COVID-19 infection. This study evaluated five candidate genes-including RNU6B, snRNA U6 (small nuclear RNAs) and three miRNAs (miR-320a, miR-342-3p, and miR-328) as potential endogenous normalizers for analyzing miRNA expression in the plasma of COVID-19 patients. The snRNA U6 showed greater stability using a combination of statistical algorithms (NormFinder, RefFinder, BestKeeper, and GeNorm), indicating that this snRNA can be used as a robust internal reference for analysis in the plasma of COVID-19 patients.
导致COVID-19的病毒SARS-CoV-2与其他冠状病毒相比,在结构上存在差异,这影响了传播动态和宿主反应。尽管疫苗减少了严重住院和死亡情况,但了解感染情况仍然具有挑战性,找到用于评估疾病严重程度的可行生物标志物将大有裨益。在此背景下,微小RNA(miRNA)是一类小的非编码RNA,已成为多种疾病的潜在生物标志物。然而,评估miRNA表达需要使用合适的内参基因对RT-qPCR数据进行标准化。这些内参基因的选择仍然是一个重大挑战,直接影响表达分析的准确性。尽管已经评估了包括小核RNA(snRNA)在内的几种小RNA,但对于COVID-19感染中血浆miRNA表达数据标准化的最佳内参基因仍未达成共识。本研究评估了五个候选基因,包括RNU6B、小核RNA U6以及三种miRNA(miR-320a、miR-342-3p和miR-328),作为分析COVID-19患者血浆中miRNA表达的潜在内源性标准化因子。使用多种统计算法(NormFinder、RefFinder、BestKeeper和GeNorm)组合分析表明,小核RNA U6具有更高的稳定性,这表明该小核RNA可作为COVID-19患者血浆分析的可靠内参。